-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, NMPA released the drug approval information, showing that CSPC NBP Pharmaceutical's Class 3 generic marketing application for zoledronic acid injection has been approved
.
The data show that zoledronic acid can be used for the treatment of hypercalcemia caused by malignant tumors, and in combination with standard antitumor drugs for the treatment of bone damage in patients with bone metastases from solid tumors and patients with multiple myeloma
.
In 2018, the sales of zoledronic acid in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals have exceeded 2 billion yuan
.
In addition, in 2021, it will be ranked first in the TOP20 drug varieties for the treatment of bone diseases
.
It should be noted that the 3-type generic drug of zoledronic acid injection of NBP Pharmaceuticals of CSPC is the sixth domestic enterprise of this product.
Kelun, Qilu, and Chia Tai Tianqing have been reviewed
.
It is expected in the industry that under this background, the 3 types of generic drugs of Zoledronic acid injection of NBP Pharmaceuticals of CSPC will face very fierce market competition in the future
.
In fact, the current fierce competition among pharmaceutical companies in zoledronic acid injection also shows that the antitumor drug market is hot
.
It is understood that in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals, the sales volume of anti-tumor and immunomodulatory agents in 2020 has exceeded 160 billion yuan.
The growth rate in the first half of the year was as high as 15.
30%
.
With the continuous expansion of the market, pharmaceutical companies are accelerating the deployment of the anti-tumor drug market
.
At the same time, R&D spending on oncology drugs has also started to grow
.
According to data, China's spending on oncology drugs has risen from US$640 million in 2016 to US$1.
36 billion in 2020, with a CAGR of 20.
8% in the past five years
.
Of course, as pharmaceutical companies are in full swing in the research and development of new tumor drugs, various good news about anti-tumor drugs have also begun to emerge.
.
Recently, in addition to NBP Pharmaceuticals of CSPC Group, it is reported that on January 4, the clinical application for LL-10, a new class 1 chemical drug, submitted by Shandong New Era Pharmaceuticals has also been undertaken by CDE
.
It is understood that in 2021, New Era Pharmaceuticals has submitted a total of 8 new drug clinical applications with acceptance numbers, of which 5 have been approved, mainly involving the field of anti-tumor therapy
.
In addition, before this, Hengrui Medicine also announced that two anti-tumor drugs with a research and development investment of over 640 million yuan were approved for clinical trials
.
The two drugs are apatinib mesylate tablets and SHR-1701 injection
.
Among them, SHR-1701 can promote the activation of effector T cells, and can also effectively improve the immune regulation in the tumor microenvironment, and finally effectively promote the killing of tumor cells by the immune system
.
SHR-1701 injection has carried out a number of solid tumor clinical trials in China and phase I clinical trials in Australia
.
In addition to the above companies, incomplete statistics show that more than 700 new drugs were approved for clinical trials in China last year, of which anti-tumor drugs accounted for more than half
.
Since last November alone, nearly 70 of the more than 100 new drugs that have been approved for clinical use in China have become anti-tumor drugs, involving pharmaceutical companies such as Hengrui and Junshi
.
In this context, the industry expects that domestic anti-tumor drugs will usher in a big explosion, but at the same time, the competition among companies in the future of popular drugs will also become more and more fierce
.
.
The data show that zoledronic acid can be used for the treatment of hypercalcemia caused by malignant tumors, and in combination with standard antitumor drugs for the treatment of bone damage in patients with bone metastases from solid tumors and patients with multiple myeloma
.
In 2018, the sales of zoledronic acid in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals have exceeded 2 billion yuan
.
In addition, in 2021, it will be ranked first in the TOP20 drug varieties for the treatment of bone diseases
.
It should be noted that the 3-type generic drug of zoledronic acid injection of NBP Pharmaceuticals of CSPC is the sixth domestic enterprise of this product.
Kelun, Qilu, and Chia Tai Tianqing have been reviewed
.
It is expected in the industry that under this background, the 3 types of generic drugs of Zoledronic acid injection of NBP Pharmaceuticals of CSPC will face very fierce market competition in the future
.
In fact, the current fierce competition among pharmaceutical companies in zoledronic acid injection also shows that the antitumor drug market is hot
.
It is understood that in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals, the sales volume of anti-tumor and immunomodulatory agents in 2020 has exceeded 160 billion yuan.
The growth rate in the first half of the year was as high as 15.
30%
.
With the continuous expansion of the market, pharmaceutical companies are accelerating the deployment of the anti-tumor drug market
.
At the same time, R&D spending on oncology drugs has also started to grow
.
According to data, China's spending on oncology drugs has risen from US$640 million in 2016 to US$1.
36 billion in 2020, with a CAGR of 20.
8% in the past five years
.
Of course, as pharmaceutical companies are in full swing in the research and development of new tumor drugs, various good news about anti-tumor drugs have also begun to emerge.
.
Recently, in addition to NBP Pharmaceuticals of CSPC Group, it is reported that on January 4, the clinical application for LL-10, a new class 1 chemical drug, submitted by Shandong New Era Pharmaceuticals has also been undertaken by CDE
.
It is understood that in 2021, New Era Pharmaceuticals has submitted a total of 8 new drug clinical applications with acceptance numbers, of which 5 have been approved, mainly involving the field of anti-tumor therapy
.
In addition, before this, Hengrui Medicine also announced that two anti-tumor drugs with a research and development investment of over 640 million yuan were approved for clinical trials
.
The two drugs are apatinib mesylate tablets and SHR-1701 injection
.
Among them, SHR-1701 can promote the activation of effector T cells, and can also effectively improve the immune regulation in the tumor microenvironment, and finally effectively promote the killing of tumor cells by the immune system
.
SHR-1701 injection has carried out a number of solid tumor clinical trials in China and phase I clinical trials in Australia
.
In addition to the above companies, incomplete statistics show that more than 700 new drugs were approved for clinical trials in China last year, of which anti-tumor drugs accounted for more than half
.
Since last November alone, nearly 70 of the more than 100 new drugs that have been approved for clinical use in China have become anti-tumor drugs, involving pharmaceutical companies such as Hengrui and Junshi
.
In this context, the industry expects that domestic anti-tumor drugs will usher in a big explosion, but at the same time, the competition among companies in the future of popular drugs will also become more and more fierce
.
